Oct 29

Takaichi’s success may backfire on Japan

The country’s first female prime minister is pushing on with a $2.3 trln investment plan. In this Viewsroom podcast, Breakingviews columnists debate whether it will fuel inflation and undermine the virtuous cycle that lifted the world’s fourth-largest economy out of stagnation. B ... Show More

14m 29s

Oct 22

AI enthusiasm’s breaking point

Neocloud stocks like $35 bln CoreWeave have sold off and so has their unsecured debt in recent weeks. In this Viewsroom podcast, Breakingviews columnists debate whether the damage can be contained, and if trouble in AI’s plumbing could further dent Anthropic’s weakening growth. B ... Show More

20m 58s

Oct 15

China-EU auto wars drive to in-Seine level

BYD, Geely and peers are taking the Paris Motor Show by storm, right after Beijing agreed with Brussels to cap hybrid exports. In this Viewsroom podcast, Breakingviews columnists tussle over how dominant the makers of Chinese EVs can be – and whether VW and others can fight back. ... Show More

27m 21s

Dec 2024

A checkup on weight-loss drugs

What started as a story about Hollywood waistlines has become a global phenomenon. Weight loss drugs are becoming more and more mainstream a few years after making their dramatic debut. On this weekend episode of Reuters World News, our health reporters weigh in on the impact of ... Show More

20m 17s

Jul 2023

One Thing: Weight Loss Drugs: Trend or Treatment?

A new group of drugs for type 2 diabetes and obesity have shown to be more effective for weight loss than any previous medications. Some medications like Ozempic and Wegovy have surged in popularity thanks in part to celebrity use. But who should be taking them? And are they safe ... Show More

17m 14s

Apr 2023

Those New Obesity Drugs Really Work–If You Can Afford Them

Pharmaceutical companies and insurance providers are at odds over a new class of drugs that have proven quite effective at helping people living with obesity lose weight. Bloomberg’s Robert Langreth and Emma Court join this episode to share their reporting on recent advancements ... Show More

25m 18s

Aug 2023

The weight-loss drug craze

<p>The UK government is pushing back against an attempt by some members of the House of Lords to close loopholes in transparency legislation, US bank stocks fell after Moody’s cut the credit ratings of 10 midsized banks, and the FT’s Jamie Smyth explains the craze behind new ... Show More

9m 10s

Apr 2024

Money Talks: Why weight-loss drugs will reshape the world

More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs that ... Show More

36m 59s

Apr 2024

Money Talks: Why weight-loss drugs will reshape the world

<p>More than 1bn people around the world are obese. That means there should be extraordinary demand for drugs to cure or mitigate the condition. Novo Nordisk is now Europe’s most valuable company and Eli Lilly’s market value has more than doubled. Both make the “miracle” drugs th ... Show More

36m 59s

Dec 2024

068 | The weight is over: How GLP-1 treatments are reshaping pharma and beyond

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ... Show More

11m 16s

Dec 2023

The Weight-Loss Drug Revolution, Part 1: Why These Drugs Work So Well

Today’s podcast is about the weight-loss drug revolution—which I believe might be one of the most important stories in the world right now. Despite all the attention weight-loss drugs are receiving, it’s possible that they might soon affect the world even more than we realize as ... Show More

50m 34s

The obesity drug craze is entering its n...